Oncogenic KRAS activation is responsible for the most common genetic subtype of lung cancer. Although many of the major downstream signaling pathways that KRAS engages have been defined, these ...
Gastric cancer cells can activate KRAS-driven signals, enabling autonomous tumor growth by producing their own WNT proteins. New research reveals how gastric cancer cells exploit WNT signaling for ...
Researchers identified that RASH3D19 creates a positive feedback loop that drives hyperactivity of RAS signaling and leads to tumor growth and treatment resistance Reducing RASH3D19 also reduced tumor ...
VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor more potent than other KRAS G12D inhibitors in preclinical models VS-7375, when combined with cetuximab, demonstrated strong tumor ...
Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S. commercial ...
Researchers at MUSC Hollings Cancer Center have discovered why a powerful cancer-causing gene mutation rarely appears in pancreatic tumors. The study, published in Cancer Research Communications, ...
When it comes to cancer metastasis, it takes two to tango. That was one of the key findings of a new study led by researchers at Memorial Sloan Kettering Cancer Center (MSK): The TGF-beta and RAS ...
Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Erasca, Inc. presented new preclinical data at the American Association ...
Pharmacogenomics. 2014;15(11):1507-1518. MEK/CDK4 PD-0325901 (MEKi) + palbociclib (CDK4i) NCT02022982 MEK/CDK4 Trametinib (MEKi) + palbociclib (CDK4i) NCT02065063 Representative KRAS-directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback